Tocilizumab in refractory adult Still's disease

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Arthritis care & research

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.20319PMID 20740616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab

  2010cited by this paper
• Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD).

  2010cited by this paper
• Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab

  2009cited by this paper
• A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

  2009cited by this paper
• Tocilizumab for multirefractory adult-onset Still’s disease

  2008cited by this paper
• Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

  2008cited by this paper
• Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

  2007cited by this paper
• Rapid responses to anakinra in patients with refractory adult-onset Still's disease.

  2005cited by this paper
• Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

  2005cited by this paper
• Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases

  2004cited by this paper
• Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.

  2004cited by this paper
• Etanercept in the treatment of adult patients with Still's disease.

  2002cited by this paper
• Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.

  2002cited by this paper
• Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease.

  2001cited by this paper
• Anti-interleukin 6 receptor antibody treatment in rheumatic disease

  2000cited by this paper
• Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease.

  1998cited by this paper
• Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

  1998cited by this paper
• Interleukin 6: a possible marker of disease activity in adult onset Still's disease.

  1996cited by this paper
• Preliminary criteria for classification of adult Still's disease.

  1992cited by this paper
• Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed up for more than 10 years.

  1990cited by this paper

• Clustering reveals diagnostic overlap between Still's disease and a hyperinflammatory subset of seronegative rheumatoid arthritis.

  2026cites this paper
• Clinical, biological, and radiological changes under therapy, and criteria for clinical response and remission in adult-onset Still’s disease: a systematic literature review informing the development of EULAR criteria for assessing disease activity

  2025cites this paper
• The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still’s disease

  2025cites this paper
• Enfermedad de Still del adulto

  2025cites this paper
• Managing the clinical heterogeneity of patients with still's disease, from early diagnosis to timely treatment.

  2025cites this paper
• The diagnostic dilemma of adult-onset Still’s disease: a case report

  2024cites this paper
• Disease activity score for still’s disease

  2024cites this paper
• CRP and sCD25 help distinguish between adult‐onset Still's disease and HLH

  2024cites this paper
• Adult-onset Still's Disease (AOSD) with Gastrointestinal Lesions

  2024cites this paper
• Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still's disease: An analysis of a Japanese claims database

  2023cites this paper
• Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease

  2023cites this paper
• Adult-onset Still’s Disease: A Case Report

  2023cites this paper
• Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts

  2023cites this paper
• Pyroptosis: the potential eye of the storm in adult-onset Still’s disease

  2023cites this paper
• Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry.

  2022cites this paper
• Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline

  2022cites this paper
• DGRh-S2e-Leitlinie

  2022cites this paper
• Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment

  2022cites this paper
• Perspectives on the use of non-biological pharmacotherapy for adult-onset Still’s disease

  2022cites this paper
• New insights on multigenic autoinflammatory diseases

  2022cites this paper
• Adult-onset Still’s disease: A disease at the crossroad of innate immunity and autoimmunity

  2022cites this paper
• The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients.

  2022cites this paper
• Interleukin-18: a biomarker with therapeutic potential in adult-onset Still’s disease

  2022cites this paper
• Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications.

  2022cites this paper
• BTT_A_290329 21..34

  2022cites this paper
• Progress in Biological Therapies for Adult-Onset Still’s Disease

  2022cites this paper
• Adult-Onset Still’s Disease: A Case Report and Review of Current Therapeutic Options

  2022cites this paper
• Diagnosis and Treatment of Adult-Onset Still’s Disease

  2021cites this paper
• Effectiveness of subcutaneous tocilizumab in refractory adult Still’s disease: report of three cases and a review of the literature

  2021cites this paper
• A review on applications of abatacept in systemic rheumatic diseases.

  2021cites this paper
• Interluekin-6 inhibitors for the treatment of adult-onset Still's disease.

  2021cites this paper
• Increased Lipid Peroxidation May Be Linked to Ferritin Levels Elevation in Adult-Onset Still’s Disease

  2021cites this paper
• The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response

  2021cites this paper
• Severe Adult Still's Disease Complicated by Purtscher-Like Retinopathy Treated with Intravenous Pulse Methylprednisolone and Tocilizumab

  2021cites this paper
• An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics

  2021cites this paper
• Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease

  2021cites this paper
• Current and emerging biological therapy in adult-onset Still’s disease

  2021cites this paper
• [Adult-onset Still's disease complications].

  2020cites this paper
• Response to: ‘Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’’ by Muraviov and Muraviova

  2020cites this paper
• A Case Report on Adult-Onset Still’s Disease Successfully Treated With Tocilizumab: A Brief Review on its Safety and Efficacy

  2020cites this paper
• Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease

  2020cites this paper
• Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review

  2020cites this paper
• Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

  2020cites this paper
• Successful use of short-term add-on tocilizumab for refractory adult-onset still’s disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide

  2020cites this paper
• Treating Adult-Onset Still Disease With Tocilizumab

  2020influential citation
• Adult‐onset still’s disease and treatment results with tocilizumab

  2020cites this paper
• Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still’s disease: when dosage matters in overcoming secondary therapy resistance

  2020cites this paper
• Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’

  2020cites this paper
• Biologics for the treatment of adult-onset still’s disease

  2019cites this paper
• Periodic and Non-Periodic Fevers

  2019cites this paper
• Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

  2019cites this paper
• Inhibiting inflammatory cytokines in adult onset Still’s disease. Current trends and new therapeutic perspectives

  2019cites this paper
• Rapid responses to golimumab in refractory adult-onset Still's disease: A case report and review of the literature

  2019cites this paper
• Tocilizumab for the treatment of adult-onset Still’s disease

  2019influential citation
• Adult-Onset Still’s Disease

  2019cites this paper
• Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: A meta-analysis

  2018influential citation
• Evidence-based clinical practice guideline for adult Still’s disease

  2018cites this paper
• Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review

  2018cites this paper
• Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review

  2018cites this paper
• Adult-Onset Still’s Disease: Molecular Pathophysiology and Therapeutic Advances

  2018cites this paper
• A comprehensive review on adult onset Still's disease.

  2018cites this paper
• Mechanisms, biomarkers and targets for adult-onset Still’s disease

  2018cites this paper
• Pathogenesis of adult onset still’s disease: current understanding and new insights

  2018cites this paper
• Anakinra for the treatment of adult-onset Still’s disease

  2018cites this paper
• Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

  2018cites this paper
• Letter to Editor: Rheumatology practice in Post Ebola Republic of Liberia, West Africa: Personal experience

  2018cites this paper
• Wirksamkeits- und Sicherheitsanalyse von Off-label-Biologikatherapien bei Patienten mit autoinflammatorischen Erkrankungen

  2018cites this paper
• CHARACTERISTICS OF ADULT-ONSET STILL’S DISEASE IN THE 21ST CENTURY

  2018cites this paper
• Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review

  2018cites this paper
• Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review

  2018cites this paper
• Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease

  2017cites this paper
• Adult-Onset Still’s Disease: Still a Serious Health Problem (a Case Report and Literature Review)

  2017cites this paper
• Serum Levels of Interleukin 33 and Soluble ST2 Are Associated with the Extent of Disease Activity and Cutaneous Manifestations in Patients with Active Adult-onset Still’s Disease

  2017cites this paper
• Severe Adult-onset Still Disease with Constrictive Pericarditis and Pleuritis That Was Successfully Treated with Tocilizumab in Addition to Corticosteroids and Cyclosporin A

  2017cites this paper
• An update: current and prospective treatments for adult-onset Still’s disease

  2017cites this paper
• [Still's disease in children and adults].

  2017cites this paper
• [Still's disease in children and adults].

  2017cites this paper
• Morbus Still im Kindes- und Erwachsenenalter

  2017cites this paper
• Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies

  2017cites this paper
• Treatment of adult-onset still’s disease: up to date

  2017cites this paper
• Morbus Still im Kindes- und Erwachsenenalter

  2017cites this paper
• Active Adult-onset Still ' s Disease Extent of Disease Activity and Cutaneous Manifestations in Patients with Serum Levels of Interleukin 33 and Soluble ST 2 Are Associated with the and

  2017cites this paper
• Fever of Unknown Origin with Polyarthritis

  2017cites this paper
• Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease

  2017cites this paper
• A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease

  2017cites this paper
• [Adult-onset Still's disease].

  2016cites this paper
• Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases.

  2016cites this paper
• Fever of Unknown Origin with Polyarthritis

  2016cites this paper
• [Adult-onset Still's disease].

  2016cites this paper
• Adult-onset Still's disease: Advances in the treatment.

  2016cites this paper
• Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease.

  2016influential citation
• A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?

  2016cites this paper
• Seizing the clinical presentation in adult onset Still's disease. An extensive literature review.

  2015cites this paper
• Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease.

  2015cites this paper
• The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study

  2015cites this paper
• [Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update].

  2015cites this paper
• Adult-onset Still's disease—pathogenesis, clinical manifestations, and new treatment options

  2015cites this paper
• Two cases of adult-onset Still's disease treated with tocilizumab that achieved tocilizumab-free remission.

  2015cites this paper
• IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions.

  2015cites this paper
• Eosinophilic Pneumonia: Autoinmune or Immunoallergic Phenomenon? Neumonía eosinofílica, ¿fenómeno autoinmune o inmunoalérgico?

  2015cites this paper